CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0378 (clinicaltrials.gov NCT No: NCT00936936)
Title:High-dose chemotherapy for poor-prognosis relapsed germ-cell tumors
Principal Investigator:Yago Nieto
Treatment Agent:Bevacizumab; Carboplatin; Docetaxel; Etoposide; Gemcitabine; Ifosfamide; Melphalan
Study Status:Open
Study Description:The goal of this clinical research study is to learn if bevacizumab, when given
in combination with 2 cycles of high-dose chemotherapy, can help to control
germ-cell tumors. The first cycle of chemotherapy will include the drugs
gemcitabine, docetaxel, melphalan, and carboplatin. The second cycle of
chemotherapy will include the drugs ifosfamide, carboplatin, and etoposide. The
safety of these drug combinations will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Testis
Phase of Study:Phase II
Treatment Agents:Bevacizumab
Carboplatin
Docetaxel
Etoposide
Gemcitabine
Ifosfamide
Melphalan
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Three to four weeks, to be repeated in a second cycle
Supported By:N/A
Return Visit:About 1 month, 100 days, 6 months and 1 year after your second stem cell
transplant. Further evaluations can be done by primary care provider.
Home Care:No home treatment required


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yago Nieto
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults